Cetuximab (C225, Erbitux) in combination with irinotecan, infusional 5-fluorouracil (5-FU) and folinic acid (FA) is safe and active in patients (pts) with metastatic colorectal cancer (CRC) expressing epidermal growth factor-receptor (EGFR). Results of a phase I study

• Book ID: 117659838
• Publisher: Elsevier Science
• Year: 2002
• Tongue: English
• Weight: 306 KB
• Volume: 38
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/s0959-8049(02)81149-2